<DOC>
	<DOCNO>NCT00645853</DOCNO>
	<brief_summary>The purpose study provide safety tolerability data AZD0837 long-term treatment ( 5 year ) patient non-valvular atrial fibrillation ( AF ) one additional risk factor stroke systemic embolic event ( moderate high risk patient ) .</brief_summary>
	<brief_title>Long-term Safety Atrial Fibrillation Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<criteria>Patients paroxysmal , persistent permanent Non Valvular Atrial Fibrillation one additional risk factor stroke systemic embolic event complete treatment study drug D1250C00008 . Atrial Fibrillation secondary reversible disorder , eg hyperthyroidism Presence valvular heart disease , mechanical heart valve , active endocarditis , leave ventricular aneurysm thrombus , atrial myxoma condition Atrial Fibrillation require chronic anticoagulation treatment Myocardial infarction , heart surgery percutaneous coronary intervention ( PCI ) within previous three month prior inclusion ; Stroke and/or systemic embolism within previous 30 day prior inclusion Conditions associate increase risk major bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>